Table of Contents Table of Contents
Previous Page  294 / 812 Next Page
Information
Show Menu
Previous Page 294 / 812 Next Page
Page Background

S290

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348

neurological soft signs (

r

=

0.44), sequence of motor acts sub-

score (

r

=

0.54) and sensory integration subscore (

r

=

0.47) in SZ

patients group (

P

< 0.05).

Conclusions

There is association between implicit motor learning

deficits and neurological soft signs in SZ patients.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.619

EW502

First-generation versus

second-generation antipsychotic

drugs for depression in schizophrenia

M. Corbo

, T. Acciavatti , S. Marini , E. Cinosi , L. Di Tizio ,

L. Di Caprio , D. Viceconte , L. Matteo , D.I. Giuseppe ,

G. Martinotti , M. Di Giannantonio

University “G.D. Annunzio” Chieti, Neuroscienze- Imaging e Scienze

Cliniche, Chieti, Italy

Corresponding author.

Introduction

A certain degree of depressive symptoms is com-

mon in schizophrenic patients. The assessment and treatment of

depressive symptoms in schizophrenia is clinically challenging.

Objectives

We conducted a cross-sectional study to investigate

the depressive dimension of schizophrenic patients.

Aims

The aim was to evaluate the effect of pharmacotherapy on

depressive symptomatology.

Methods

Thirty-four outpatients (18-65 years old) with stable

schizophrenia in monotherapy with FGAs or SGAs. We evalu-

ated: depressive symptoms with Calgary Depression Scale for

Schizophrenia; positive and negative symptoms (with Positive

and Negative Symptom Scale); neurocognition (with Matrics

Cognitive Consensus Battery); social cognition (with Facial Emo-

tional Identification Test); social functioning (with Personal and

Social Performance Scale and with UCSD Performance-based Skills

Assessment). Collected data underwent statistical analyses.

Results

A SGAs therapy was associated with: lower depressive

symptoms (mean SGAs group = 4.0; mean FGAs group = 7.86,

P

< 0.05); lower mean positive symptoms (mean SGAs

group = 12.65; mean FGAs group = 17.43,

P

< 0.05); lower

negative symptoms (mean SGAs group = 21.35; mean FGAs

group = 29.07,

P

< 0.05); lower scores on the PANSS-total (mean

SGAs group = 71.05; mean FGAs group = 91.86,

P

< 0.01). After cor-

rection for multiple variables, the SGAs group still had significantly

lower values towards the FGAs group (

P

< 0.05).

Conclusions

Our study support the notion that switch from a

FGA to a SGA could be a relatively simple first-step for the treat-

ment of this condition. Atypical antipsychotics might exercise

antidepressant effects with different potential mechanism includ-

ing: remission of a FGA-induced depression and action on of

5-hydroxytryptamine, dopamine [other than postsynaptic D2], and

1-noradrenergic receptor sites.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.620

EW503

Clinical and functioning outcomes of

second-generation long-acting

antipsychotics in a sample of

schizophrenia patients during a

follow-up period of 6 months

V. Corigliano

1 ,

, I. Mancinelli

1

, A. De Carolis

2

, S.M. Tamorri

1

,

S. Di Pietro

1

, F. Pazzelli

1

, I. Ciccaglione

1

, P. Girardi

1

,

A. Comparelli

1

1

Sant’Andrea hospital, NESMOS department neurosciences- mental

health and sense organs unit of psychiatry- Sant’Andrea hospital-

school of medicine and psychology- Sapienza university, Roma, Italy

2

Sant’Andrea hospital, NESMOS department neurosciences- mental

health and sense organs unit of psychological medicine- Sant’Andrea

hospital- school of medicine and psychology- Sapienza university,

Roma, Italy

Corresponding author.

Introduction

Second-generation long-acting injectable antipsy-

chotics (LAIs) constitute a valuable alternative for the treatment

of schizophrenia and combine advantages of both long-acting

injectable drugs and atypical antipsychotics. Realistic, naturalis-

tic studies are necessary to evaluate the impact of LAIs on specific

cluster of symptoms.

Objectives

To collect clinical and functioning outcomes in out-

patients with schizophrenia treated with LAIs during a follow-up

period of 6 months.

Aims

To determine the impact on symptoms and functioning of

second-generation LAIs.

Methods

It is a 6-month naturalistic, observational, prospec-

tive, non-interventional study of patients diagnosed with DSM-V

schizophrenia disorder. Clinical data were assessed by the Positive

and Negative Syndrome Scale (PANSS) and the Global Assessment

of Functioning (GAF). For statistical analysis, we used the Wall-

work’s five-factor model of the PANSS.

Results

A total of 50 schizophrenia patients (70% male; mean

age: 36.2

±

10.4) referred to the Depot Clinic at Sant’Andrea Hospi-

tal in Rome was included. Eight patients received treatment with

risperidone LAI (RLAI), 20 with paliperidone-palmitate LAI (PLAI),

10 with olanzapine-pamoate LAI (OLAI) and 12 with aripiprazole

LAI (ALAI). LAIs were overall associated with improved function-

ing and positive symptoms; OLAI, ALAI e PLAI correlated with

improved negative symptoms, RLAI, OLAI e PLAI with improved dis-

organised/concrete symptoms, OLAI e PLAI with improved excited

symptoms; ALAI improved depressive symptoms.

Conclusion

Over the 6-month period, LAIs were associated with

improved functioning and illness severity in schizophrenia patients

with different symptoms profile. Treatment with PLAI and OLAI

showed the major clinical advantages, whereas only ALAI corre-

lated with improved depressive symptoms.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.621

EW504

Reduction of negative social

attributions towards people with

mental illness through a combination

of treatments

C. Vaquero

1 ,

, M. Cebollero

1

, M.Á. Escudero

1

, J. Saiz

1 , 2

1

Grupo 5, psychosocial rehabilitation, Aranjuez, Spain

2

Universidad Complutense de Madrid, Facultad de Psicología,

Madrid, Spain

Corresponding author.

Introduction

Stigma towards people withmental illness can have

very negative consequences for the persons that experience it. So,

it becomes strongly necessary to combat this problem.

Objectives/Aims

Evaluate the effectiveness of multiple interven-

tions to reduce stigma against mental illness in a group of high

school students.

Methods

Quasi-experimental study.

Seventy-six students

between 16 to 19 years old from 3 schools of southern Madrid

State participated. No significant differences in age and gen-

der between groups were found. The quasi-control group was

obtained from 3 different classrooms (1 in each school). This

group did not go through any treatment. The experimental group